

# Bram L T Ramaekers

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/375997/publications.pdf>

Version: 2024-02-01

70  
papers

1,557  
citations

361296

20  
h-index

330025

37  
g-index

72  
all docs

72  
docs citations

72  
times ranked

3097  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer. <i>Acta Oncologica</i> , 2022, 61, 619-624.	0.8	0
2	Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2021, 39, 171-180.	1.7	4
3	Comment on "External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions" <i>Pharmacoeconomics</i> , 2021, 39, 133-135.	1.7	1
4	Prognostic and Predictive Value of Integrated Qualitative and Quantitative Magnetic Resonance Imaging Analysis in Glioblastoma. <i>Cancers</i> , 2021, 13, 722.	1.7	24
5	Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to "TRUST4RD: tool for reducing uncertainties in the evidence generation for) <i>Tj ETQq</i> 1.1 0.784314 rgBT	1.1	14
6	Modeling-Based Decision Support System for Radical Prostatectomy Versus External Beam Radiotherapy for Prostate Cancer Incorporating an In Silico Clinical Trial and a Cost-Utility Study. <i>Cancers</i> , 2021, 13, 2687.	1.7	1
7	High-sensitivity troponin assays for early rule-out of acute myocardial infarction in people with acute chest pain: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2021, 25, 1-276.	1.3	16
8	Individual patient data meta-analysis of prophylactic cranial irradiation in locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2021, 158, 40-47.	0.3	7
9	State of the ART? Two New Tools for Risk Communication in Health Technology Assessments. <i>Pharmacoeconomics</i> , 2021, 39, 1185-1196.	1.7	4
10	Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study. <i>Value in Health</i> , 2021, 24, 983-994.	0.1	7
11	Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2021, 39, 1429-1442.	1.7	10
12	Implementation Barriers to Value of Information Analysis in Health Technology Decision Making: Results From a Process Evaluation. <i>Value in Health</i> , 2021, 24, 1126-1136.	0.1	4
13	Optimizing the Use of High-Sensitivity Troponin Assays for the Early Rule-out of Myocardial Infarction in Patients Presenting with Chest Pain: A Systematic Review. <i>Clinical Chemistry</i> , 2021, 67, 237-244.	1.5	17
14	Association of different fractionation schedules for prophylactic cranial irradiation with toxicity and brain metastases-free survival in stage III non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trials. <i>Radiotherapy and Oncology</i> , 2021, 164, 163-166.	0.3	0
15	Health-related quality of life after prophylactic cranial irradiation for stage III non-small cell lung cancer patients: Results from the NVALT-11/DLCRG-02 phase III study. <i>Radiotherapy and Oncology</i> , 2020, 144, 65-71.	0.3	15
16	Development and Validation of the TRansparent Uncertainty ASsessmentT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models. <i>Pharmacoeconomics</i> , 2020, 38, 205-216.	1.7	23
17	Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry. <i>Quality of Life Research</i> , 2020, 29, 3363-3374.	1.5	11
18	An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry. <i>Acta Oncologica</i> , 2020, 59, 1123-1130.	0.8	3

#	ARTICLE	IF	CITATIONS
19	R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study. <i>Pharmacoeconomics</i> , 2020, 38, 765-776.	1.7	6
20	Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients â€“ A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103035.	2.0	5
21	Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands. <i>PLoS ONE</i> , 2020, 15, e0230909.	1.1	7
22	Title is missing!. , 2020, 15, e0230909.		0
23	Title is missing!. , 2020, 15, e0230909.		0
24	Title is missing!. , 2020, 15, e0230909.		0
25	Title is missing!. , 2020, 15, e0230909.		0
26	Clinically inappropriate post hoc exclusion of study participants from test accuracy calculations: the ROMA score, an example from a recent NICE diagnostic assessment. <i>Annals of Clinical Biochemistry</i> , 2019, 56, 72-81.	0.8	1
27	Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 1195-1207.	1.7	8
28	Comparison of three generic quality-of-life metrics in peripheral arterial disease patients undergoing conservative and invasive treatments. <i>Quality of Life Research</i> , 2019, 28, 2257-2279.	1.5	9
29	Quality of Life After Stereotactic Radiotherapy for Early-Stage Lung Cancer: Mission Accomplished?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 326-327.	0.5	0
30	Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 887-894.	1.7	13
31	Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory?. <i>Value in Health</i> , 2019, 22, 799-807.	0.1	14
32	Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 655-667.	1.7	8
33	Telemonitoring in patients with heart failure: Is there a long-term effect?. <i>Journal of Telemedicine and Telecare</i> , 2019, 25, 158-166.	1.4	10
34	Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018, 36, 917-927.	1.7	7
35	Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018, 36, 533-543.	1.7	2
36	Trifluridineâ€“Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018, 36, 285-288.	1.7	5

#	ARTICLE	IF	CITATIONS
37	Development of an isotoxic decision support system integrating genetic markers of toxicity for the implantation of a rectum spacer. <i>Acta Oncologica</i> , 2018, 57, 1499-1505.	0.8	6
38	Economic evaluation of an expert examiner and different ultrasound models in the diagnosis of ovarian cancer. <i>European Journal of Cancer</i> , 2018, 100, 55-64.	1.3	5
39	EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 429-432.	1.0	12
40	Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research. <i>Pharmacoeconomics</i> , 2018, 36, 105-113.	1.7	5
41	The Prevention of Brain Metastases in Non-Small Cell Lung Cancer by Prophylactic Cranial Irradiation. <i>Frontiers in Oncology</i> , 2018, 8, 241.	1.3	18
42	Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2018, 22, 1-264.	1.3	106
43	Decision support systems for personalized and participative radiation oncology. <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 131-153.	6.6	113
44	Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal". <i>Pharmacoeconomics</i> , 2017, 35, 665-667.	1.7	0
45	Development of a virtual spacer to support the decision for the placement of an implantable rectum spacer for prostate cancer radiotherapy: Comparison of dose, toxicity and cost-effectiveness. <i>Radiotherapy and Oncology</i> , 2017, 125, 107-112.	0.3	23
46	What is the impact of innovation on output in healthcare with a special focus on treatment innovations in radiotherapy? A literature review. <i>British Journal of Radiology</i> , 2017, 90, 20170251.	1.0	13
47	Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 485-498.	1.1	8
48	Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017, 35, 191-202.	1.7	8
49	Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium. <i>Oncotarget</i> , 2017, 8, 79223-79233.	0.8	21
50	Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement. <i>Radiotherapy and Oncology</i> , 2016, 121, 440-446.	0.3	15
51	Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives. <i>Pharmacoeconomics</i> , 2016, 34, 315-322.	1.7	19
52	European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer. <i>European Journal of Cancer</i> , 2016, 63, 168-179.	1.3	8
53	Development and evaluation of an online three-level proton vs photon decision support prototype for head and neck cancer "Comparison of dose, toxicity and cost-effectiveness. <i>Radiotherapy and Oncology</i> , 2016, 118, 281-285.	0.3	65
54	ImmunoCAP® ISAC and Microtest for multiplex allergen testing in people with difficult to manage allergic disease: a systematic review and cost analysis. <i>Health Technology Assessment</i> , 2016, 20, 1-178.	1.3	34

#	ARTICLE	IF	CITATIONS
55	Spacers in radiotherapy treatment of prostate cancer: Is reduction of toxicity cost-effective?. Radiotherapy and Oncology, 2015, 114, 276-281.	0.3	49
56	Cost-Effectiveness of Reduced Waiting Time for Head and Neck Cancer Patients due to a Lean Process Redesign. Value in Health, 2015, 18, 587-596.	0.1	9
57	A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis. Pharmacoeconomics, 2015, 33, 205-224.	1.7	84
58	High-sensitivity troponin assays for the early rule-out or diagnosis of acute myocardial infarction in people with acute chest pain: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2015, 19, 1-234.	1.3	39
59	Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2015, 19, 1-236.	1.3	114
60	H-Target model: Early technology assessment for ext generation sequencing in oncology.. Journal of Clinical Oncology, 2015, 33, 6604-6604.	0.8	0
61	Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2014, 18, 1-166.	1.3	42
62	KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2014, 18, 1-132.	1.3	66
63	How Should We Deal with Patient Heterogeneity in Economic Evaluation: A Systematic Review of National Pharmacoeconomic Guidelines. Value in Health, 2013, 16, 855-862.	0.1	35
64	Acknowledging Patient Heterogeneity in Economic Evaluation. Pharmacoeconomics, 2013, 31, 111-123.	1.7	55
65	Protons in Head-and-Neck Cancer: Bridging the Gap of Evidence. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1282-1288.	0.4	71
66	Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non-Small-Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2013, 8, 1295-1307.	0.5	16
67	Systematic review and meta-analysis of radiotherapy in various head and neck cancers: Comparing photons, carbon-ions and protons. Cancer Treatment Reviews, 2011, 37, 185-201.	3.4	86
68	The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy. Oral Oncology, 2011, 47, 768-774.	0.8	94
69	Adherence Among Telemonitored Patients with Heart Failure to Pharmacological and Nonpharmacological Recommendations. Telemedicine Journal and E-Health, 2009, 15, 517-524.	1.6	31
70	Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. The Cochrane Library, 2009, , CD006158.	1.5	41